A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis

Journal of Gastroenterology
Akihito NagaharaKen Haruma

Abstract

Proton pump inhibitors (PPIs) are affected by cytochrome P450 2C19 (CYP2C19) polymorphisms. This study compared the effect of two PPIs on early symptom relief in Japanese patients with reflux esophagitis, classified by the CYP2C19 phenotype. Patients with reflux esophagitis were randomised to treatment with omeprazole 20 mg or rabeprazole 10 mg once daily. The CYP2C19 phenotype [homozygous extensive metaboliser (homoEM), heterozygous extensive metaboliser (heteroEM) or poor metaboliser (PM)] of each patient was determined. The primary efficacy endpoint was early, sufficient (Global Overall Symptom scale score 1 or 2), sustained (maintained for ≥7 days) reflux symptom relief. Of the 199 patients included in this analysis, the proportion achieving sufficient, sustained reflux symptom relief was higher with omeprazole than with rabeprazole on day 1 (35.6 vs. 22.4%; p = 0.041) and day 2 (43.6 vs. 28.6%; p = 0.028); there was no significant difference between the two groups on days 3-7. Among patients with the CYP2C19 PM phenotype, sufficient, sustained reflux symptom relief was higher with omeprazole than with rabeprazole on days 4-7 (62.5-66.9 vs. 31.6%; p ≤ 0.03); differences were not significant on days 1-3, or among those with ...Continue Reading

References

Oct 1, 1996·Alimentary Pharmacology & Therapeutics·A S Mee, J L Rowley
May 26, 1999·Clinical Pharmacology and Therapeutics·T FurutaT Ishizaki
Aug 10, 2000·Alimentary Pharmacology & Therapeutics·C A Stedman, M L Barclay
Sep 13, 2001·Alimentary Pharmacology & Therapeutics·J P GalmicheT J Humphries
Dec 12, 2001·Alimentary Pharmacology & Therapeutics·N ShiraiT Ishizaki
Sep 25, 2002·Alimentary Pharmacology & Therapeutics·T SaitohS Ohkawa
May 19, 2005·Current Medical Research and Opinion·Athanasios J ArchimandritisUNKNOWN Hellenic Rabeprazole Study Group
Aug 16, 2005·Alimentary Pharmacology & Therapeutics·F PaceUNKNOWN ITALIAN ONE INVESTIGATORS STUDY GROUP
Jan 13, 2006·The American Journal of Gastroenterology·Ingela WiklundNimish Vakil
Jan 31, 2006·Alimentary Pharmacology & Therapeutics·S J O Veldhuyzen van ZantenK Nevin
Jul 5, 2006·The American Journal of Gastroenterology·Sander Veldhuyzen van ZantenAlly Gasco
Jul 18, 2006·Alimentary Pharmacology & Therapeutics·P WahlqvistA Barkun
Aug 25, 2006·The American Journal of Gastroenterology·Nimish VakilUNKNOWN Global Consensus Group
Sep 23, 2006·Scandinavian Journal of Gastroenterology·Peter BytzerUNKNOWN ROSE Trial Investigators
Apr 9, 2008·World Journal of Gastroenterology : WJG·Hatsushi YamagishiTooru Shimosegawa
Jun 23, 2011·Journal of Gastroenterology·Yoshikazu KinoshitaKen Haruma
Sep 29, 2011·The American Journal of Gastroenterology·Jukka RonkainenPertti Aro
Nov 15, 2011·Journal of Gastroenterology·Kazunari TominagaUNKNOWN GERD 4 Study Group
Aug 23, 2012·Journal of Gastroenterology·Nobuyuki MatsukiTakeshi Azuma

❮ Previous
Next ❯

Citations

Nov 19, 2015·Journal of Gastroenterology and Hepatology·Hitomi IchikawaTakahisa Furuta
Apr 21, 2020·Oxidative Medicine and Cellular Longevity·Márcia Fernanda Correia Jardim PazAna Amélia de Carvalho Melo Cavalcante
Sep 2, 2017·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·L HillmanJ E Pandolfino

❮ Previous
Next ❯

Methods Mentioned

BETA
fluorescence correlation spectroscopy

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.